HeartLungs AI Gains FDA Clearance

- HeartLung AI's clearance covers ten opportunistic screening applications on a single platform, making it the most comprehensive FDA-cleared tool of its kind for CT imaging. The AI analyzes existing chest and abdominal CT scans to provide measurements for conditions like coronary heart disease, osteoporosis, and fatty liver disease without new scans or radiation exposure. - The technology is designed to be applied to a massive existing dataset—nearly 40 million CT scans performed in the U.S. annually, which is about half of all CT scans performed. This creates a scalable method for population health screening by extracting more clinical value from imaging that has already been performed. - The AI in medical imaging market is projected to grow significantly, with one forecast predicting an increase from USD 1.36 billion in 2024 to USD 19.78 billion by 2033. This growth is driven by the demand for early diagnosis and the increasing volume of imaging data. - Competitors in the AI-driven opportunistic screening space include Nanox AI (formerly Zebra Medical Vision), which has an FDA-cleared product called HealthCCSng for calculating coronary artery calcium (CAC) scores from chest CTs. Major imaging vendors like GE HealthCare, Siemens Healthineers, and Philips also have numerous FDA-cleared AI applications integrated into their platforms. - This clearance aligns with a broader industry shift toward value-based care and preventative medicine, leveraging AI to identify at-risk patients before symptoms appear. The American Heart Association has noted the potential of opportunistic screening on non-cardiac chest CTs to improve cardiovascular disease risk stratification without additional costs or radiation. - The growth of outpatient imaging centers creates a significant market for technologies like HeartLungs AI. As health systems expand their freestanding imaging assets through acquisitions or new construction, efficiency tools that add diagnostic value to routine scans become operationally and financially attractive. - Reimbursement models are evolving to recognize the value of advanced imaging and AI. While the 2025 Medicare Physician Fee Schedule includes an overall reduction, specific codes like those for coronary computed tomography angiography (CCTA) have seen significant reimbursement increases, signaling growing support for advanced cardiovascular diagnostics. Additionally, CMS will begin unbundling and separately reimbursing for high-cost diagnostic radiopharmaceuticals in 2025.